Llorens-Cebrià Carmen, Núñez-Seral Norberto, Villena-Ortiz Yolanda, Martínez-Díaz Irene, Soler Maria José, Ferrer-Costa Roser, Jacobs-Cachá Conxita, López-Hellín Joan
Nephrology and Transplantation Research Group, Vall d'Hebrón Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.
High Technology Unit. Vall d'Hebrón Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.
J Am Soc Mass Spectrom. 2024 Oct 2;35(10):2267-2271. doi: 10.1021/jasms.4c00155. Epub 2024 Sep 20.
Apolipoprotein A-I (ApoA-I), one of the most abundant proteins in plasma and the major protein component of high-density lipoprotein (HDL), is naturally found in several proteoforms; two of them are ProApoA-I and mature ApoA-I. These two proteoforms of ApoA-I coexist in biological samples and differ only in their N-terminal end. Virtually, the only way to differentiate them is by detecting the proteoform-specific N-terminal proteolytic peptides (RHFWQQDEPPQSPWDR and DEPPQSPWDR, respectively) using liquid chromatography in multiple reaction monitoring mode mass spectrometry (LC-MRM-MS). We have developed a bottom-up LC-MRM-MS method to simultaneously detect proApoA-I and mature ApoA-I. To test the specificity of the method, we digested with trypsin purified mature ApoA-I and recombinant proApoA-I. As expected, only the N-term peptide corresponding to the mature ApoA-I proteoform (DEPPQSPWDR) was detected when digesting mature ApoA-I. However, the digestion of the proApoA-I produced not only the N-terminal peptide corresponding to proApoA-I (RHFWQQDEPPQSPWDR) but also the N-terminal tryptic peptide corresponding to mature ApoA-I (DEPPQSPWDR). This effect was produced by standard and high-specificity trypsin as well as by the Arg-C enzyme in a self-limited manner (approximately 10% of the total). The synthetic proApo-I peptide is not cleaved by trypsin, suggesting that the here reported effect is dependent on protein conformation. The effect is not negligible, as it can be detected by LC-MRM-MS, and correction calculations should be applied to accurately quantify proApoA-I and mature ApoA-I in biological samples where these two proteoforms may coexist.
载脂蛋白A-I(ApoA-I)是血浆中含量最丰富的蛋白质之一,也是高密度脂蛋白(HDL)的主要蛋白质成分,天然存在多种蛋白形式;其中两种是前ApoA-I和成熟ApoA-I。这两种ApoA-I蛋白形式在生物样品中共存,仅在N端有所不同。实际上,区分它们的唯一方法是使用液相色谱-多反应监测模式质谱(LC-MRM-MS)检测蛋白形式特异性的N端蛋白水解肽(分别为RHFWQQDEPPQSPWDR和DEPPQSPWDR)。我们开发了一种自下而上的LC-MRM-MS方法来同时检测前ApoA-I和成熟ApoA-I。为了测试该方法的特异性,我们用胰蛋白酶消化纯化的成熟ApoA-I和重组前ApoA-I。正如预期的那样,消化成熟ApoA-I时仅检测到与成熟ApoA-I蛋白形式对应的N端肽(DEPPQSPWDR)。然而,前ApoA-I的消化不仅产生了与前ApoA-I对应的N端肽(RHFWQQDEPPQSPWDR),还产生了与成熟ApoA-I对应的N端胰蛋白酶肽(DEPPQSPWDR)。标准的高特异性胰蛋白酶以及Arg-C酶均以自限方式(约占总量的10%)产生这种效应。合成的前Apo-I肽不会被胰蛋白酶切割,这表明此处报道的效应取决于蛋白质构象。这种效应不可忽略,因为它可以通过LC-MRM-MS检测到,在这两种蛋白形式可能共存的生物样品中,应进行校正计算以准确量化前ApoA-I和成熟ApoA-I。